Insta
COVAXIN, India’s first indigenous vaccine against Coronavirus. (Swarajya Magazine)
Early results from the first phase of Bharat Biotech - Indian Council For Medical Research (ICMR) developed vaccine for Covid-19, named Covaxin, indicate that the vaccine is safe, Economic Times has reported.
At present trials are on for the vaccine with 375 volunteers across 12 sites in the country. Each volunteer has received two doses of the vaccine.
"We have no observed any adverse events in any of the volunteers at our site", one of the principal investigators is quoted by ET as saying.
At the All India Institute of Medical Sciences (AIIMS), Delhi the team is preparing for administering the second dose and so so far no adverse effects have been observed. Sixteen volunteers are involved with the vaccine trials at AIIMs.
The vaccine, being developed from a SARS-CoV-2 strain of the virus isolated by the National Institute of Virology, Pune, is much looked forward to by the union government. ET quotes an anonymous investigator saying that if everything goes according to plan the vaccine may be available in the market as early as first half of the next year.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest